Cargando…

Cyclic (68)Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2

In this study, we developed angiotensin-converting enzyme 2 (ACE2)–specific, peptide-derived (68)Ga-labeled radiotracers, motivated by the hypotheses that ACE2 is an important determinant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptibility and that modulation of ACE2 in co...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, Matthew F.L., Blecha, Joseph, Rosenberg, Oren, Ohliger, Michael, Flavell, Robert R., Wilson, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612341/
https://www.ncbi.nlm.nih.gov/pubmed/33637588
http://dx.doi.org/10.2967/jnumed.120.261768
_version_ 1784603439898034176
author Parker, Matthew F.L.
Blecha, Joseph
Rosenberg, Oren
Ohliger, Michael
Flavell, Robert R.
Wilson, David M.
author_facet Parker, Matthew F.L.
Blecha, Joseph
Rosenberg, Oren
Ohliger, Michael
Flavell, Robert R.
Wilson, David M.
author_sort Parker, Matthew F.L.
collection PubMed
description In this study, we developed angiotensin-converting enzyme 2 (ACE2)–specific, peptide-derived (68)Ga-labeled radiotracers, motivated by the hypotheses that ACE2 is an important determinant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptibility and that modulation of ACE2 in coronavirus disease 2019 (COVID-19) drives severe organ injury. Methods: A series of NOTA-conjugated peptides derived from the known ACE2 inhibitor DX600 were synthesized, with variable linker identity. Since DX600 bears 2 cystine residues, both linear and cyclic peptides were studied. An ACE2 inhibition assay was used to identify lead compounds, which were labeled with (68)Ga to generate peptide radiotracers ((68)Ga-NOTA-PEP). The aminocaproate-derived radiotracer (68)Ga-NOTA-PEP4 was subsequently studied in a humanized ACE2 (hACE2) transgenic model. Results: Cyclic DX-600–derived peptides had markedly lower half-maximal inhibitory concentrations than their linear counterparts. The 3 cyclic peptides with triglycine, aminocaproate, and polyethylene glycol linkers had calculated half-maximal inhibitory concentrations similar to or lower than the parent DX600 molecule. Peptides were readily labeled with (68)Ga, and the biodistribution of (68)Ga-NOTA-PEP4 was determined in an hACE2 transgenic murine cohort. Pharmacologic concentrations of coadministered NOTA-PEP (blocking) showed a significant reduction of (68)Ga-NOTA-PEP4 signals in the heart, liver, lungs, and small intestine. Ex vivo hACE2 activity in these organs was confirmed as a correlate to in vivo results. Conclusion: NOTA-conjugated cyclic peptides derived from the known ACE2 inhibitor DX600 retain their activity when N-conjugated for (68)Ga chelation. In vivo studies in a transgenic hACE2 murine model using the lead tracer, (68)Ga-NOTA-PEP4, showed specific binding in the heart, liver, lungs and intestine—organs known to be affected in SARS-CoV-2 infection. These results suggest that (68)Ga-NOTA-PEP4 could be used to detect organ-specific suppression of ACE2 in SARS-CoV-2–infected murine models and COVID-19 patients.
format Online
Article
Text
id pubmed-8612341
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Society of Nuclear Medicine
record_format MEDLINE/PubMed
spelling pubmed-86123412022-05-01 Cyclic (68)Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2 Parker, Matthew F.L. Blecha, Joseph Rosenberg, Oren Ohliger, Michael Flavell, Robert R. Wilson, David M. J Nucl Med Basic Science Investigation In this study, we developed angiotensin-converting enzyme 2 (ACE2)–specific, peptide-derived (68)Ga-labeled radiotracers, motivated by the hypotheses that ACE2 is an important determinant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptibility and that modulation of ACE2 in coronavirus disease 2019 (COVID-19) drives severe organ injury. Methods: A series of NOTA-conjugated peptides derived from the known ACE2 inhibitor DX600 were synthesized, with variable linker identity. Since DX600 bears 2 cystine residues, both linear and cyclic peptides were studied. An ACE2 inhibition assay was used to identify lead compounds, which were labeled with (68)Ga to generate peptide radiotracers ((68)Ga-NOTA-PEP). The aminocaproate-derived radiotracer (68)Ga-NOTA-PEP4 was subsequently studied in a humanized ACE2 (hACE2) transgenic model. Results: Cyclic DX-600–derived peptides had markedly lower half-maximal inhibitory concentrations than their linear counterparts. The 3 cyclic peptides with triglycine, aminocaproate, and polyethylene glycol linkers had calculated half-maximal inhibitory concentrations similar to or lower than the parent DX600 molecule. Peptides were readily labeled with (68)Ga, and the biodistribution of (68)Ga-NOTA-PEP4 was determined in an hACE2 transgenic murine cohort. Pharmacologic concentrations of coadministered NOTA-PEP (blocking) showed a significant reduction of (68)Ga-NOTA-PEP4 signals in the heart, liver, lungs, and small intestine. Ex vivo hACE2 activity in these organs was confirmed as a correlate to in vivo results. Conclusion: NOTA-conjugated cyclic peptides derived from the known ACE2 inhibitor DX600 retain their activity when N-conjugated for (68)Ga chelation. In vivo studies in a transgenic hACE2 murine model using the lead tracer, (68)Ga-NOTA-PEP4, showed specific binding in the heart, liver, lungs and intestine—organs known to be affected in SARS-CoV-2 infection. These results suggest that (68)Ga-NOTA-PEP4 could be used to detect organ-specific suppression of ACE2 in SARS-CoV-2–infected murine models and COVID-19 patients. Society of Nuclear Medicine 2021-11 /pmc/articles/PMC8612341/ /pubmed/33637588 http://dx.doi.org/10.2967/jnumed.120.261768 Text en © 2021 by the Society of Nuclear Medicine and Molecular Imaging. https://creativecommons.org/licenses/by/4.0/Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.
spellingShingle Basic Science Investigation
Parker, Matthew F.L.
Blecha, Joseph
Rosenberg, Oren
Ohliger, Michael
Flavell, Robert R.
Wilson, David M.
Cyclic (68)Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2
title Cyclic (68)Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2
title_full Cyclic (68)Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2
title_fullStr Cyclic (68)Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2
title_full_unstemmed Cyclic (68)Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2
title_short Cyclic (68)Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2
title_sort cyclic (68)ga-labeled peptides for specific detection of human angiotensin-converting enzyme 2
topic Basic Science Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612341/
https://www.ncbi.nlm.nih.gov/pubmed/33637588
http://dx.doi.org/10.2967/jnumed.120.261768
work_keys_str_mv AT parkermatthewfl cyclic68galabeledpeptidesforspecificdetectionofhumanangiotensinconvertingenzyme2
AT blechajoseph cyclic68galabeledpeptidesforspecificdetectionofhumanangiotensinconvertingenzyme2
AT rosenbergoren cyclic68galabeledpeptidesforspecificdetectionofhumanangiotensinconvertingenzyme2
AT ohligermichael cyclic68galabeledpeptidesforspecificdetectionofhumanangiotensinconvertingenzyme2
AT flavellrobertr cyclic68galabeledpeptidesforspecificdetectionofhumanangiotensinconvertingenzyme2
AT wilsondavidm cyclic68galabeledpeptidesforspecificdetectionofhumanangiotensinconvertingenzyme2